Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.

Autor: Bota, Daniela A.1 (AUTHOR) dbota@hs.uci.edu, Taylor, Thomas H.1,2 (AUTHOR), Piccioni, David E.3 (AUTHOR), Duma, Christopher M.4 (AUTHOR), LaRocca, Renato V.5 (AUTHOR), Kesari, Santosh6 (AUTHOR), Carrillo, Jose A.4,6 (AUTHOR), Abedi, Mehrdad7 (AUTHOR), Aiken, Robert D.8 (AUTHOR), Hsu, Frank P. K.1 (AUTHOR), Kong, Xiao-Tang1 (AUTHOR), Hsieh, Candace9 (AUTHOR), Bota, Peter G.9,10 (AUTHOR), Nistor, Gabriel I.9 (AUTHOR), Keirstead, Hans S.9 (AUTHOR), Dillman, Robert O.9 (AUTHOR)
Zdroj: Journal of Experimental & Clinical Cancer Research (17569966). 12/14/2022, Vol. 41 Issue 1, p1-9. 9p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje